101 results
Page 3 of 6
8-K
EX-99.1
wokey0wpg3bj07b1x
9 Aug 21
Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update
4:27pm
8-K
EX-99.1
2prt4h7fxx
6 May 21
Gossamer Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update
8:06am
8-K
EX-99.1
ooivyzx
25 Feb 21
Gossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Update
8:00am
8-K
EX-99.1
4spkaxz4 o7ii
10 Nov 20
Gossamer Bio Announces Third Quarter 2020 Financial Results and Provides Corporate Update
4:14pm
8-K
EX-99.1
7mif2uw5 d96jh
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
8-K
7pbced s03
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
8-K
EX-99.2
1hh40r7v
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
8-K
EX-99.1
83tfl8s3
11 Aug 20
Gossamer Bio Announces Second Quarter 2020 Financial Results and Provides Corporate Update
4:30pm
8-K
EX-1.2
fc8tjppu6vvvfv1irbg
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
EX-99.1
eft73
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
EX-99.2
mbis lg3x
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
EX-1.1
knag y3xx
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
424B5
acsb5z 75glh8
19 May 20
Prospectus supplement for primary offering
5:11pm
424B5
ejfah69
19 May 20
Prospectus supplement for primary offering
5:08pm
FWP
dpeongjr3pqgs1zg 5f
18 May 20
Free writing prospectus
5:02pm
424B5
q6m pldfjy38h
18 May 20
Prospectus supplement for primary offering
4:16pm